Hematopoietic Stem Cell Transplants from Unrelated Donors

Summary

Further improvements in the safety and efficacy of unrelated donor transplants can be expected with better GVHD prevention and facilitation of tolerance induction. New approaches such as selected depletion of distinct T cell subsets, use of purified stem cells and novel forms of immune modulation using biologicals and other engineered molecules are promising, but additional preclinical and appropriate clinical trials must be undertaken before the full potential benefits as well as limitations of these new approaches are known.